Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo

Circulation

Volumn 110, Issue 14, 2004, Pages 2053-2059

  Buerkle, Martin A ^a   Lehrer, Selim ^a   Sohn, Hae Young ^a   Conzen, Peter ^a   Pohl, Ulrich ^a   Krötz, Florian ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Aspirin; Endothelium; Platelets; Prostaglandins; Thrombosis

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FERRIC CHLORIDE; FLUORESCENT DYE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIOLE; ARTICLE; BLOOD VESSEL OCCLUSION; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL INTERACTION; CONTROLLED STUDY; DRUG SELECTIVITY; ENDOTHELIUM CELL; ENZYME INHIBITION; FLUORESCENCE; HAMSTER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROCIRCULATION; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOSIS;

6-KETOPROSTAGLANDIN F1 ALPHA; ADENOSINE DIPHOSPHATE; ANIMALS; ARTERIOLES; ASPIRIN; CELLS, CULTURED; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; ILOPROST; MEMBRANE PROTEINS; MESOCRICETUS; NITROBENZENES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SKIN WINDOW TECHNIQUE; SULFONAMIDES; THROMBOPHILIA; UMBILICAL VEINS;

EID: 4944241808     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000143234.51796.A9     Document Type: Article

References (31)

1. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol. 2002;63:817-821.
2. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
3. Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol. 2002;39:521-522.
4. Hankey GJ, Eikelboom JW. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not? Stroke. 2003;34:2736-2740.
5. FitzGerald GA. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol. 2002;89:26D-32D.
6. FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
7. Baber SR, Champion HC, Bivalacqua TJ, et al. Role of cyclooxygenase-2 in the generation of vasoactive prostanoids in the rat pulmonary and systemic vascular beds. Circulation. 2003;108:896-901.
8. McAdam BF, Mardini IA, Habib A, et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest. 2000;105:1473-1482.
9. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
10. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
11. Buerkle MA, Pahernik SA, Sutler A, et al. Inhibition of the α-v integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer. 2002;86:788-795.
12. Krotz F, Sohn HY, Keller M, et al. Depolarization of endothelial cells enhances platelet aggregation through oxidative inactivation of endothelial NTPDase. Arterioscler Thromb Vasc Biol. 2002;22:2003-2009.
13. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95:9524-9529.
14. Krotz F, Sohn HY, Gloe T, et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood. 2002;100:917-924.
15. Krotz F, Riexinger T, Buerkle MA, et al. Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol. 2004;24:595-600.
16. Hennan JK, Huang J, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation. 2001;104:820-825.
17. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
18. de Gaetano G, Donati MB, Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol Sci. 2003;24:245-252.
19. Shinmura K, Tang XL, Wang Y, et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A. 2000;97:10197-10202.
20. Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the presser response to angiotensin II. J Clin Invest. 2002;110:61-69.
21. Cerletti C, Gambino MC, Garattini S, et al. Biochemical selectivity of oral versus intravenous aspirin in rats: inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels. J Clin Invest. 1986;78:323-326.
22. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol. 2000;40:1509-1515.
23. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40:1109-1120.
24. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
25. 2. Science. 2002;296:539-541.
26. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
27. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
28. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
29. Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol. 1997;48:623-631.
30. Konstam MA, Weir MR. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med. 2002;69(suppl 1):SI47-SI52.
31. Mukherjee D, Topol EJ. Pharmaceutical advertising versus research spending: are profits more important than patients? Am Heart J. 2003;146:563-564.